Akari TherapeuticsAKTX
13F holders, Q3 2025 (September 30)16holders +1
3new positions
2sold out
$1.01avg. 13F price*
At the end of Q3 2025, 16 institutions reported holding Akari Therapeutics PLC (AKTX) in their 13F filings, up 1 from Q2 2025. 3 opened new positions and 2 sold out. The largest holders were Cresset Asset Management, LLC ($831K), Palo Alto Investors LP ($147K) and HighTower Advisors, LLC ($80K).
- Company
- Akari Therapeutics PLC
- CUSIP
- 00972G207
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $53K |
| Exits | 2 | $231K |
All 13F filers, Q2 2025 → Q3 2025: 857,204 shares bought and 237,877 shares sold, net +619,327 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 16 holders
| Cresset Asset Management, LLC | 0.00% | Add +4368.0% | 822,468 | $831K |
| Palo Alto Investors LP | 0.03% | No change | 146,024 | $147K |
| HighTower Advisors, LLC | 0.00% | No change | 79,236 | $80K |
| Omnia Family Wealth, LLC | 0.01% | Reduce -54.6% | 28,440 | $29K |
| Cerity Partners LLC | 0.00% | No change | 23,643 | $24K |
| Virtu Financial LLC | 0.00% | New | 22,502 | $22K |
| Two Sigma Securities, LLC | 0.00% | New | 19,753 | $20K |
| Independent Advisor Alliance | 0.00% | New | 10,887 | $11K |
| Accent Capital Management, LLC | 0.00% | No change | 10,000 | $10K |
| NewEdge Advisors, LLC | 0.00% | No change | 6,800 | $7K |
| Cornerstone Planning Group LLC | 0.00% | Add +40.0% | 7 | $285 |
| Bank of America Corp. | 0.00% | No change | 150 | $152 |
| UBS Group AG | 0.00% | Reduce -97.2% | 60 | $61 |
| Truvestments Capital LLC | 0.00% | No change | 50 | $51 |
| EverSource Wealth Advisors, LLC | 0.00% | Reduce -99.0% | 44 | $44 |
| Morgan Stanley | 0.00% | No change | 3 | $3 |
"% of holder's portfolio" is AKTX's weight in each manager's 13F, not the share of Akari Therapeutics PLC the manager owns.